Bright Uro Builds AI Data Asset as Glean Urodynamics Adoption Expands

Bright Uro is a urology-focused medtech company, and this weekly summary highlights a series of advances centered on its FDA-cleared Glean Urodynamics System and new data initiatives. The company launched the Glean Registry to collect de-identified real-world data from commercial use of Glean, aiming to fuel future device development and clinical research.

The registry is designed to underpin Bright Uro’s Urodynamic Intelligence platform, which applies AI and machine learning to a large urodynamics dataset to build algorithms that may assist in interpreting test results. Executives describe the registry as a strategic data asset intended to accelerate understanding of lower urinary tract dysfunction and support AI- and ML-based diagnostic tools.

By aggregating standardized, high-quality signals from its wireless, catheter-free Glean platform, Bright Uro aims to create one of the most comprehensive repositories of urodynamics data. This approach could enhance product differentiation, support decision-support tools in urology, and align the company with broader medtech trends toward evidence generation and AI-enabled diagnostics.

During the week, Bright Uro also spotlighted growing clinical adoption of Glean across several U.S. sites, including Middlesex Health Urology in Connecticut and New Jersey Urology, a Summit Health company. Clinicians at these centers reported that Glean is easier to learn than traditional systems and may enable urodynamic studies at every clinic location instead of a single centralized site.

Vandalia Health in West Virginia and Urology Specialists Clinic and Ambulatory Surgical Center in South Dakota were highlighted as early adopters, with the latter described as the first Glean user in the state. Physicians there indicated that the system allows urodynamic diagnostics in any exam room, improving patient comfort and staff efficiency and serving as a potential reference for further regional expansion.

Bright Uro further emphasized manufacturing quality and clinician engagement through a visit by urologist Dr. Jason Kim to its headquarters and production facility. His positive feedback on care, precision, and craftsmanship in the manufacturing process was presented as reinforcing confidence in the technology and supporting broader clinical adoption.

These developments collectively suggest Bright Uro is pairing a data-centric, AI-enabled strategy with expanding real-world use of its urodynamics platform. While no financial metrics were disclosed, increased site adoption, favorable usability feedback, and the build-out of a proprietary data registry appear to strengthen the company’s clinical credibility and competitive position in the urology diagnostics market.

Overall, the week was constructive for Bright Uro, marked by meaningful progress in both technological infrastructure and market penetration for the Glean Urodynamics System.